All the agents used commonly i.v. to induce anaesthesia have been shown to decrease intracranial pressure (i.c.p.) (Horsley, 1937; Hunter, 1972; Turner et al., 1973) and cerebral blood flow (c.b.f.) (Pierce et al., 1962; Herrschaft et al., 1975; Sari et al., 1976) , with the sole exception of ketamine, ""which increases both i.c.p. (Evans et al., 1971; Gardner, Olson and Lichtiger, 1971; Takeshita, Okuda and Sari, 1972) and c.b.f. (Dawson, Michenfelder and Theye, 1971; Takeshita, Okuda and Sari, 1972) . Etomidate, an i.v. agent, has been introduced recently for induction of anaesthesia and has the advantages of cardiovascular stability (Doenicke, 1974; Morgan, Lumley and Whitwam, 1975; Holdcroft et al., 1976; Rifat, Gamulin and Gemperle, 1976; Famewo and Odugbesan, 1977; Ghoneim and Yamada, 1977; Lees and Hendry, 1977; Patschke et al., 1977) , freedom from marked respiratory depression (Doenicke, 1974; Whitwam, 1975,1977; Famewo and Odugbesan, 1977,1978; Ghoneim and Yamada, 1977) , and rapid inactivation (Kay, 1976; Lees and Hendry, 1977) . It has been shown by Herrschaft and his co-workers (1975) that etomidate decreases c.b.f. in normal man, and thus it would be expected to reduce i.c.p. also. This study was undertaken to determine the effect of etomidate on i.c.p. in patients with intracranial pathology who were about to undergo craniotomy, and thus to determine its suitability for use in patients with intracranial space-occupying lesions.
METHODS
Ten patients with intracranial lesions requiring craniotomy were investigated. All gave their informed consent for the study. If considered necessary, the patients were premedicated with diazepam 10 mg i.m. Anaesthesia was induced with thiopentone, which was given until the eyelash reflex was obtunded, and was maintained with nitrous oxide 70% in oxygen. Ventilation was controlled using a Manley Pulmovent ventilator and tubocurarine 45 mg was administered to produce neuromuscular blockade. The volume of ventilation was adjusted to produce normocapnia and this was maintained constant throughout the period of the study. Allen's test was performed on all the patients and, if there was adequate ulnar collateral circulation, a radial artery cannula was inserted. After infiltration of the scalp with local analgesic a burr hole was made, through which a catheter was inserted into a lateral ventricle. The radial artery and ventricular cannulae were connected to suitably calibrated transducers, the signals from which were amplified and recorded on chart recorders. The zero reference for the arterial transducer was the midaxillary line (with the patient supine, tilted 10°h ead-up), and for the ventricular transducer was the external auditory meatus. The arterial pressure and intracranial pressure traces were observed for 5 min before the injection of etomidate 0. Samples were taken for measurement of arterial blood-gas tensions just before the administration of the etomidate (initial Pa co^) and at 10 min after the administration of etomidate (final Pa C oJ-During the period of measurement the end-tidal carbon dioxide concentration was monitored continuously with an infra-red gas analyser.
RESULTS
The ages and diagnoses of all the patients and their mean i.c.p. during the control period, and at 2-min intervals after the administration of etomidate are in table I. It was found that i.c.p. decreased initially in all the patients and then started to increase, but in only two patients, it returned to control values within the 10 min ( fig. 1 ). This decrease from control was statistically significant (0.01 >P> 0.001) at the 1st min after injection, and remained significant at the 1% level or greater for the 10 min of measurement.
There was a small decrease in m.a.p. in eight patients which was significant statistically at 3 and 4 min after the administration of etomidate (0.05 > P>0.02) (table II). The heart rate decreased slightly in eight patients but did not differ significantly from the control value at any time.
On average c.p.p. decreased slightly, but this decrease never reached statistical significance (table  III, fig. 2 ). In only one patient did the c.p.p. decrease to less than 60 mm Hg (patient B, minimum c.p.p. = 54 mm Hg). It can be seen (table IV) that in five patients PacQj, was in the lower part of the normal range, and in four patients just below the lower limit of normal. One patient was markedly hypocapnic In most patients there was a slight decrease in Pa C02 over the 10-min period of measurement, so that mean Pa C02 decreased by 0.23 kPa (statistically significant: 0.01 >P> 0.001). The decrease in the end-tidal carbon dioxide concentration occurred usually at between 2 and 7 min after the administration of etomidate. Figure 3 shows the scatter diagram and regression line for the decrease in i.c.p. after the administration 
DISCUSSION
It is known that thiopentone, methohexitone and Althesin reduce i.c.p. (Horsley, 1937; Hunter, 1972; Turner et al., 1973) and c.b.f. (Pierce et al., 1962; Herrschaft et al., 1975; Sari et al., 1976 ), but that ketamine increases i.c.p. (Evans et al., 1971; Gardner, Olson and Lichtiger, 1971; Wyte et al., 1972) and c.b.f. (Dawson, Michenfelder and Theye, 1971; Takeshita, Okuda and Sari, 1972) . In the presence of intracranial space-occupying lesions, it is preferable to use agents which either do not affect i.c.p. or which decrease it. Thus, it is important to determine the effect on i.c.p. of any new anaesthetic agent, such as etomidate, to ascertain its suitability for use in patients with increased i.c.p. In this study there was a decrease in i.c.p. in all 10 patients following the administration of etomidate i.v. This reduction can be explained ahnost certainly by the rapid decrease in c.b.f., and thus cerebral blood volume, which is known to occur after the administration of etomidate (Herrschaft et al., 1975) . Herrschaft's studies were in normal patients anaesthetized with propanidid, suxamethonium, nitrous oxide, oxygen and halothane 0.1-0.4 vol%. The use of halothane may explain the more short-lived reduction in c.b.f. that they observed (less than 5 min) as compared with the duration of the decrease in i.c.p. that we observed (more than 10 min). The duration of the decrease in i.c.p. seen in our study is more in keeping with the duration of action of etomidate reported in the literature both by Doenicke (1974) , who reported that the time to complete recovery after the administration of etomidate 0.3 mg kg" 1 was approximately 12 min, and by Lewi and Heykants (1978) who found that the plasma concentration decreased by approximately 90% in 16 min after a dose of 0.21 mgkg"
1 . The numbers in this present series were inadequate to show whether there was a greater decrease in i.c.p. if the i.c.p. was high initially.
The small decrease in Pa C02 (average 0.23 kPa), noted in most of the patients during the period of measurement, occurred during constant ventilation which had been established for at least 30 min before the administration of etomidate. It may have been a result of a reduction in metabolic rate, and thus a reduction in carbon dioxide production. With one exception this decrease in Pa C02 occurred between 2 and 7 min after the administration of etomidate, whereas the maximum change in i.c.p. occurred within 90 s, and by 7 min i.c.p. was beginning to increase again. Thus, the influence on i.c.p. of this small change in Pa cc , 2 was probably minimal.
Although the m.a.p. decreased in all but two patients, the lowest m.a.p. recorded was 77 mm Hg which was above the value at which the autoregulation of c.b.f. ceases and c.b.f. becomes pressure-dependent. The c.p.p. increased in 50%of the patients and decreased in 50%, remaining adequate in all. The heart rate decreased slightly in most of the patients, but the change was not significant statistically. These findings confirm the cardiovascular stability found with etomidate (Doenicke, 1974; Morgan, Lumley and Whitwam, 1975; Holdcroft et al., 1976; Rifat, Gamulin and Gemperle, 1976; Famewo and Odugbesan, 1977; Ghoneim and Yamada, 1977; Lees and Hendry, 1977; Patschke et al., 1977) .
There are other possible advantages of etomidate which were not assessed in this study. Plasma histamine concentration does not increase after its administration (Doenicke et al., 1973) (whereas it does after Althesin and propanidid), and as yet there is no reported case of allergic reaction to the drug. In the dose required for anaesthesia, respiratory depression is not a problem (Doenicke, 1974; Whitwam, 1975, 1977; Famewo and Odugbesan, 1977, 1978; Ghoneim and Yamada, 1977) , although this is not so important in neuroanaesthesia as ventilation is usually controlled. Etomidate is metabolized quickly and, judged on clinical grounds in man, is not cumulative (Kay, 1976; Lees and Hendry, 1977) . Thus, its use by continuous i.v. infusion may have a place, as an alternative to methohexitone (Hunter, 1972) or Althesin, in maintaining anaesthesia in patients with intracranial space-occupying lesions. The rapid metabolism of the drug and its ability to reduce i.c.p. suggest that it would be suitable for the rapid reduction of i.c.p. in patients with head injuries, or for prophylactic use before chest physiotherapy or other procedures known to increase i.c.p. in this group of patients.
On the basis of this study, we conclude that etomidate would be a useful addition to the drugs available to the neuroanaesthetist for the induction of anaesthesia, a conclusion which is supported by recent reports by Cunitz, Danhauser and Wickbold (1978) and Schulte am Esch, Pfeifer and Thiemig (1978) . In addition, it could be used as an agent for the rapid reduction of i.c.p. and possibly for maintenance of anaesthesia by continuous infusion.
Note added in proof: Since this manuscript was prepared, Renou and colleagues (1978) 
SUMARIO
Diez pacientes con lesiones intracraneales, anestesiados con tiopentona y oxido nitroso (70%) en oxigeno (30%), recibieron etomidata 0,2 mg kg" 1 intravenosamente. La ventilacion fue controlada en todos los pacientes. Se registro la presion intracraneal (I.C.P.) y presion arterial media (M.A.P.). La I.C.P. disminuyo significativamente en todos los pacientes (0,01 >P>0,001). Aunque el Pa C o, disminuyo durante el periodo de medicion, la magnitud y el transcurso de tiempo de este cambio sugirieron que no era principalmente responsable de los cambios en la I.C.P. La M.A.P. disminuyo en la mayoria de los pacientes, pero la disminucion fue estadisticamente significativa solamente despues de 3 y 4 min de administrarse etomidata (0,05>P>0,02). Los cambios en la presion de perfusion cerebral (C.P.P.) y en los latidos del coraz6n no fueron clinica ni estadisticamente significativos. Concluimos que la etomidata puede emplearse para la induction de anestesia en pacientes con lesiones intracraneales que ocupan espacio, sin aumentar la I.C.P. ni reducir seriamente la C.P.P.
